Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints

Eloxx Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.34

Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.
Cash $24.6M as of Sep 30, 2022; expects funding into Q4 2023 subject to covenant compliance.
Phase 2 Alport trial (NCT05448755) dosed first patient; topline results expected H1 2023.
Phase 2 CF combination (ELX-02 + ivacaftor) did not meet efficacy endpoints; path forward to be determined with CF Foundation.
ZKN-013 IND for RDEB on track for end of 2022 / early 2023; preclinical data presented for TURBO-ZM platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eloxx Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: net income net loss of $7.5 million, or $0.09 per share, EPS $0.09 per share.

Period: three months ended September 30, 2022
Net income: net loss of $7.5 million, or $0.09 per share
EPS: $0.09 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, we incurred a net loss of $7.5 million, or $0.09 per share, which included $0.7 million in stock-based compensation.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-118535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.